Related content

Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus

By Forst Thomas   Pfützner Andreas  

Expert Review of Endocrinology and Metabolism, Vol. 8, Iss. 1, 2013-01 ,pp. : 21-35

Informa Healthcare

Access to resources Recommend Favorite

Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus

By Sasaki Takashi  

Diabetology International, Vol. 1, Iss. 2, 2010-12 ,pp. : 90-92

Springer Publishing Company

Access to resources Recommend Favorite

Linagliptin: A Novel Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor for Treatment of Type II Diabetes Mellitus

By  

Current Diabetes Reviews, Vol. 7, Iss. 5, 2011-09 ,pp. : 325-335

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial

By Charbonnel B.   Steinberg H.   Eymard E.   Xu L.   Thakkar P.   Prabhu V.   Davies M.   Engel S.  

Diabetologia, Vol. 56, Iss. 7, 2013-07 ,pp. : 1503-1511

Springer Publishing Company

Access to resources Recommend Favorite

Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients

By  

Current Vascular Pharmacology, Vol. 14, Iss. 6, 2016-10 ,pp. : 552-562

Bentham Science Publishers

Access to resources Recommend Favorite